Inhibition of platelet aggregation using anti-human GPVI antibodies
AssigneesActicor Biotech, Université Paris Cité, Université Paris-XIII, Inserm (Institut National De La Sante Et De La Recherche Medicale), Universite Paris-Saclay
InventorsPhilippe Billiald, Martine Jandrot-Perrus, Gilles Avenard
Life of this patent
Estimating the term…
Abstract
The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.
Claims20
A method for treating a cardiovascular disease or event associated with inflammation and/or thrombosis in a subject in need thereof comprising administering an isolated humanized protein binding to human Glycoprotein VI (hGPVI), wherein said isolated humanized protein is administered for at least 2 hours, wherein said isolated humanized protein is a monovalent antibody fragment, wherein
- the variable region of the heavy chain of the antibody fragment comprises the following CDRs:
- VH-CDR1:
- (SEQ ID NO:
- 1)
- GYTFTSYNMH;
- VH-CDR2:
- (SEQ ID NO:
- 2)
- GIYPGNGDTSYNQKFQG;
- and
- VH-CDR3:
- (SEQ ID NO:
- 3)
- GTVVGDWYFDV;
- and
- the variable region of the light chain of the antibody fragment comprises the following CDRs:
- VL-CDR1:
- (SEQ ID NO:
- 4)
- RSSQSLENSNGNTYLN;
- VL-CDR2:
- (SEQ ID NO:
- 5)
- RVSNRFS;
- and
- VL-CDR3:
- (SEQ ID NO:
- 6)
- LQLTHVPWT.
Dependencies are inferred from the claim text.